Over several years, there has been mounting evidence that a deficiency in special immune cells called T-regulatory (Treg) cells, which are essential for preparing the uterus for receptive embryo ...
London, UK – October 22, 2024 – Quell Therapeutics Ltd (“Quell”), a leader in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune ...
Tumor tissue and ascites from patients with ovarian cancer contain high levels of cells with all the hallmarks of regulatory T cells. These cells migrate into the tumor microenvironment in a ...
Taiwan’s REGiMMUNE and Europe-based Kiji Therapeutics are merging to create a globally minded regulatory T-cell biotech that already has its eyes set on an IPO. REGiMMUNE’s lead therapy ...